Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data

• Published in: Supportive care in cancer Vol. 30; no. 6; pp. 5137 - 5146
• Main Authors: den Hollander, Dide, Dirkson, Anne R., Verberne, Suzan, Kraaij, Wessel, van Oortmerssen, Gerard, Gelderblom, Hans, Oosten, Astrid, Reyners, Anna K. L., Steeghs, Neeltje, van der Graaf, Winette T. A., Desar, Ingrid M. E., Husson, Olga
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2022; Springer; Springer Nature B.V
• Subjects: Algorithms; Antimitotic agents; Antineoplastic agents; Care and treatment; Cross-Sectional Studies; Data mining; Fatigue - epidemiology; Gastric cancer; Gastrointestinal cancer; Gastrointestinal Stromal Tumors - drug therapy; Humans; Imatinib Mesylate - adverse effects; Inhibitor drugs; Machine learning; Medical research; Medicine; Medicine & Public Health; Medicine, Experimental; Muscle Cramp; Muscle pain; Nursing; Nursing Research; Oncology; Original; Original Article; Pain Medicine; Patients; Protein Kinase Inhibitors - adverse effects; Quality of Life; Questionnaires; Rehabilitation Medicine; Skin diseases; Social networks; Surveys; Surveys and Questionnaires; Symptom management; Targeted cancer therapy; Tumors; Tyrosine; Social media mining; Patient-reported outcomes; Symptom measurement; Patient forum; Tyrosine kinase inhibitors; Gastrointestinal stromal tumours

Purpose Treatment with the tyrosine kinase inhibitor (TKI) imatinib in patients with gastrointestinal stromal tumours (GIST) causes symptoms that could negatively impact health-related quality of life (HRQoL). Treatment-related symptoms are usually clinician-reported and little is known about patien...